Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:688131'
s ROE % Range Over the Past 10 Years
Min: 5.28 Med: 14.44 Max: 40.66
Current: 7.95
During the past 13 years, Shanghai Haoyuan Chemexpress Co's highest ROE % was 40.66%. The lowest was 5.28%. And the median was 14.44%.
SHSE:688131's ROE % is ranked better than 56.78% of 937
companies
in the Drug Manufacturers industry
Industry Median: 6.04
vs SHSE:688131: 7.95
Shanghai Haoyuan Chemexpress Co (SHSE:688131) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Shanghai Haoyuan Chemexpress Co ROE % Related Terms
Shanghai Haoyuan Chemexpress Co ROE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Haoyuan Chemexpress Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Haoyuan Chemexpress Co ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shanghai Haoyuan Chemexpress Co's ROE % distribution charts can be found below:
* The bar in red indicates where Shanghai Haoyuan Chemexpress Co's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Shanghai Haoyuan Chemexpress Co (SHSE:688131) has a ROE % of 8.55% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Shanghai Haoyuan Chemexpress Co and its competitors. This is 41% below median its historical median of 14.44. Over the past decade, Shanghai Haoyuan Chemexpress Co's ROE % has ranged from 5.28 to 40.66. According to the industry distribution chart, Shanghai Haoyuan Chemexpress Co ranks #405 out of 937 companies in the Drug Manufacturers industry, placing it in the top 43.2%.
Is Shanghai Haoyuan Chemexpress Co's ROE % too high?
Shanghai Haoyuan Chemexpress Co's current ROE % of 8.55% is 41% below median its 10-year median of 14.44. Over the past 10 years, this metric has ranged from a low of 5.28 to a high of 40.66. The Drug Manufacturers industry median ROE % is 6.04. Shanghai Haoyuan Chemexpress Co's value of 8.55% is 41.6% above this industry median. Based on the distribution chart, Shanghai Haoyuan Chemexpress Co ranks #405 out of 937 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Shanghai Haoyuan Chemexpress Co has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Haoyuan Chemexpress Co's ROE % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Shanghai Haoyuan Chemexpress Co ranks #405 out of 937 companies for ROE %. This puts Shanghai Haoyuan Chemexpress Co in the upper half of its industry. The industry median ROE % is 6.04. Shanghai Haoyuan Chemexpress Co's value of 8.55% is 41.6% above this benchmark. Historically, Shanghai Haoyuan Chemexpress Co's own ROE % has ranged from 5.28 to 40.66 over the past decade. While the company's 10-year median is 14.44 vs. the industry median of 6.04, Shanghai Haoyuan Chemexpress Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 6.04, based on 937 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Haoyuan Chemexpress Co's current ROE % of 8.55% is 41.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Shanghai Haoyuan Chemexpress Co and its competitors. For the Drug Manufacturers industry, the median ROE % is 6.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Haoyuan Chemexpress Co's current ROE % is 8.55%, which is 41% below median its own 10-year median of 14.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Haoyuan Chemexpress Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Haoyuan Chemexpress Co (SHSE:688131) is currently considered Fairly Valued. The stock's GF Value™ is ¥65.89, compared to a current price of ¥70.55 — trading 7.1% above its estimated fair value. The current ROE % is 8.55%, which is 41% below median its 10-year median of 14.44 and 41.6% above the Drug Manufacturers industry median of 6.04. Shanghai Haoyuan Chemexpress Co's overall GF Score™ is 92/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Shanghai Haoyuan Chemexpress Co (SHSE:688131), the current ROE % is 8.55% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Haoyuan Chemexpress Co (SHSE:688131) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Haoyuan Chemexpress Co stock appears to be overvalued.
The current stock price of ¥70.55 is trading 7.1% above its estimated GF Value™ of ¥65.89.
GuruFocus considers Shanghai Haoyuan Chemexpress Co to be Fairly Valued.
Key valuation signals for SHSE:688131:
ROE %: 8.55% (41% below median its 10-year median of 14.44)
GF Value™: ¥65.89 vs. price of ¥70.55 (7.1% above fair value)
Industry Position: 41.6% above the Drug Manufacturers median (#405 of 937)
No single metric tells the full story. See the SHSE:688131 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Haoyuan Chemexpress Co Business Description
Shanghai Haoyuan Chemexpress Co Ltd focuses on providing small molecule and new modalities CDMO services for both pharmaceutical and biotech clients. The company's comprehensive CRO & CDMO platform is engaged in the research and development, manufacturing and supply of regulatory starting materials, novel building blocks, intermediates, reference compounds, APIs and drug products. It is a one-stop service platform to support client's projects from early drug discovery, process development to commercialization. The company is committed to delivering high-quality products and CMC services to clients across the entire life cycle of drug development.
92GF Score
Get the complete analysis for SHSE:688131
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688131 has been successfully added to your 
